Malaria Stocks List

Recent Signals

Date Stock Signal Type
2021-02-26 AGEN Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2021-02-26 AGEN 1,2,3 Pullback Bullish Bullish Swing Setup
2021-02-26 CODX Fell Below 200 DMA Bearish
2021-02-26 GNCA 50 DMA Support Bullish
2021-02-26 GNCA NR7 Range Contraction
2021-02-26 GOVX NR7 Range Contraction
2021-02-26 GOVX NR7-2 Range Contraction
2021-02-26 GOVX Narrow Range Bar Range Contraction
2021-02-26 GOVX Stochastic Buy Signal Bullish
2021-02-26 INO Fell Below 50 DMA Bearish
2021-02-26 TARS NR7 Range Contraction
2021-02-26 TARS 20 DMA Resistance Bearish

Recent News for Malaria Stocks

Date Stock Title
Feb 27 INO INOVIO INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Inovio Pharmaceuticals Inc. - INO
Feb 26 INO Earnings Outlook For Inovio Pharmaceuticals
Feb 26 INO Is a Surprise Coming for Inovio (INO) This Earnings Season?
Feb 25 INO A Balanced Take on Inovio Pharmaceuticals Stock
Feb 25 CODX Co-Diagnostics COVID-19 saliva test available through Walgreens
Feb 25 CODX Co-Diagnostics, Inc. Partner to Offer At-Home Saliva Collection Kits for CoPrimer™-Based COVID-19 PCR Test Through Walgreens Find Care®
Feb 24 CODX Why Co-Diagnostics Stock Is Shooting Higher Today
Feb 24 INO Qiagen to develop a companion diagnostic for Inovio’s VGX-3100 in cervical dysplasia
Feb 24 CODX Clinical Reference Laboratory Makes First At-Home COVID-19 Saliva Test Available Through Walgreens Find Care®
Feb 24 INO The Daily Biotech Pulse: Bausch Calls Truce With Icahn, Pfizer's Brain Inflammation Vaccine Gets Priority Review, BriaCell IPO
Feb 24 INO Qiagen, Inovio In Development Pact For VGX-3100 Companion Diagnostics
Feb 24 INO INOVIO and QIAGEN expand collaboration to develop next generation sequencing (NGS) companion diagnostic for INOVIO's VGX-3100 for advanced cervical dysplasia
Feb 24 INO QIAGEN and INOVIO Expand Collaboration to Develop Next Generation Sequencing (NGS) Companion Diagnostic for INOVIO’s VGX-3100 for Advanced Cervical Dysplasia
Feb 24 CODX Co-Diagnostics Names New CFO and CSO
Feb 23 CODX Co-Diagnostics trades low, names new finance chief
Feb 23 CODX Co-Diagnostics, Inc. Announces New Chief Financial Officer
Feb 23 INO INOVIO Announces First Subject Dosed in Phase 1B Clinical Trial for its DNA Vaccine Against Lassa Fever, INO-4500, in West Africa
Feb 21 INO Are Short-Sellers Right About Inovio?

Malaria is a mosquito-borne infectious disease affecting humans and other animals caused by single-celled microorganisms belonging to the Plasmodium group. Malaria causes symptoms that typically include fever, tiredness, vomiting, and headaches. In severe cases it can cause yellow skin, seizures, coma, or death. Symptoms usually begin ten to fifteen days after being bitten by an infected mosquito. If not properly treated, people may have recurrences of the disease months later. In those who have recently survived an infection, reinfection usually causes milder symptoms. This partial resistance disappears over months to years if the person has no continuing exposure to malaria.The disease is most commonly transmitted by an infected female Anopheles mosquito. The mosquito bite introduces the parasites from the mosquito's saliva into a person's blood. The parasites travel to the liver where they mature and reproduce. Five species of Plasmodium can infect and be spread by humans. Most deaths are caused by P. falciparum because P. vivax, P. ovale, and P. malariae generally cause a milder form of malaria. The species P. knowlesi rarely causes disease in humans. Malaria is typically diagnosed by the microscopic examination of blood using blood films, or with antigen-based rapid diagnostic tests. Methods that use the polymerase chain reaction to detect the parasite's DNA have been developed, but are not widely used in areas where malaria is common due to their cost and complexity.The risk of disease can be reduced by preventing mosquito bites through the use of mosquito nets and insect repellents, or with mosquito control measures such as spraying insecticides and draining standing water. Several medications are available to prevent malaria in travellers to areas where the disease is common. Occasional doses of the combination medication sulfadoxine/pyrimethamine are recommended in infants and after the first trimester of pregnancy in areas with high rates of malaria. Despite a need, no effective vaccine exists, although efforts to develop one are ongoing. The recommended treatment for malaria is a combination of antimalarial medications that includes an artemisinin. The second medication may be either mefloquine, lumefantrine, or sulfadoxine/pyrimethamine. Quinine along with doxycycline may be used if an artemisinin is not available. It is recommended that in areas where the disease is common, malaria is confirmed if possible before treatment is started due to concerns of increasing drug resistance. Resistance among the parasites has developed to several antimalarial medications; for example, chloroquine-resistant P. falciparum has spread to most malarial areas, and resistance to artemisinin has become a problem in some parts of Southeast Asia.The disease is widespread in the tropical and subtropical regions that exist in a broad band around the equator. This includes much of Sub-Saharan Africa, Asia, and Latin America. In 2016, there were 216 million cases of malaria worldwide resulting in an estimated 445,000 to 731,000 deaths. Approximately 90% of both cases and deaths occurred in Africa. Rates of disease have decreased from 2000 to 2015 by 37%, but increased from 2014 during which there were 198 million cases. Malaria is commonly associated with poverty and has a major negative effect on economic development. In Africa, it is estimated to result in losses of US$12 billion a year due to increased healthcare costs, lost ability to work, and negative effects on tourism.

More about Malaria
Browse All Tags